Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
B5-6 T HH producing human FLC were obtained from 50 % of MM and PG cases. High numbers of MNC and CD138+ cells enabled productive fusions. The HH clones produced FLC with easily appreciated dimers and monomers in vitro and in vivo. With IP in vivo implants after 2 weeks more dimers were seen than in short term cultures in vitro. These HH clones will be made available for study of FLC metabolism and testing of therapeutics designed to abrogate FLC production or enable FLC clearance in vivo.
Authors
- Xiaobo Ma (ORCID: https://orcid.org/0000-0002-0934-5035)
- Simone Scalia
- Raymond L. Comenzo (ORCID: https://orcid.org/0000-0002-6255-5824)
- Denis Toskic (ORCID: https://orcid.org/0000-0002-3340-762X)
- Ping Zhou (ORCID: https://orcid.org/0000-0002-0643-8527)
- Luis del Pozo‐Yauner (ORCID: https://orcid.org/0000-0002-2551-0301)
- Nancy Coady Lyons
- Xia Wu (ORCID: https://orcid.org/0000-0002-2056-8344)
- Terry Fogaren
Institutions
- Tufts Medical Center (US)
- Amyloidosis Foundation (US)
- University of South Alabama (US)
Publication Details
- Journal
- Biochemistry and Biophysics Reports
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.bbrep.2025.102017
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00